U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Unresectable Renal Pelvis and Ureter Urothelial Carcinoma

MedGen UID:
1710125
•Concept ID:
C5236020
•
Neoplastic Process

Definition

Renal pelvis and ureter urothelial carcinoma that is not amenable to surgical resection. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVUnresectable Renal Pelvis and Ureter Urothelial Carcinoma

Recent clinical studies

Etiology

Difference of oncological efficacy between two immune checkpoint inhibitors following first-line platinum-based chemotherapy in patients with unresectable, metastatic, advanced urothelial carcinoma: a multicenter real-world Japanese cohort.
Miyake M, Nishimura N, Oda Y, Miyamoto T, Iida K, Inoue K, Tachibana A, Yoshikawa T, Sakamoto K, Ohnishi M, Maesaka F, Takamatsu N, Mieda K, Ohmori C, Matsubara T, Tomizawa M, Shimizu T, Ohnishi K, Hori S, Morizawa Y, Gotoh D, Nakai Y, Torimoto K, Tanaka N, Fujimoto K; Nara Urological Research and Treatment Group
Int J Clin Oncol 2024 Sep;29(9):1311-1325. Epub 2024 Jun 18 doi: 10.1007/s10147-024-02573-5. PMID: 38888683
Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre real-world Japanese cohort.
Miyake M, Nishimura N, Oda Y, Miyamoto T, Ohmori C, Takamatsu N, Itami Y, Tachibana A, Matsumoto Y, Kiba K, Tomioka A, Yamamoto H, Okajima E, Masaomi K, Sakamoto K, Tomizawa M, Shimizu T, Ohnishi K, Hori S, Morizawa Y, Gotoh D, Nakai Y, Torimoto K, Tanaka N, Fujimoto K; Nara Urological Research and Treatment Group
Jpn J Clin Oncol 2024 Mar 9;54(3):329-338. doi: 10.1093/jjco/hyad170. PMID: 38061911
Switch-maintenance avelumab immunotherapy following first-line chemotherapy for patients with advanced, unresectable or metastatic urothelial carcinoma: the first Japanese real-world evidence from a multicenter study.
Miyake M, Shimizu T, Oda Y, Tachibana A, Ohmori C, Itami Y, Kiba K, Tomioka A, Yamamoto H, Ohnishi K, Nishimura N, Hori S, Morizawa Y, Gotoh D, Nakai Y, Torimoto K, Fujii T, Tanaka N, Fujimoto K
Jpn J Clin Oncol 2023 Mar 7;53(3):253-262. doi: 10.1093/jjco/hyac186. PMID: 36484294
Immune checkpoint inhibition in upper tract urothelial carcinoma.
Califano G, Ouzaid I, Verze P, Hermieu JF, Mirone V, Xylinas E
World J Urol 2021 May;39(5):1357-1367. Epub 2020 Oct 31 doi: 10.1007/s00345-020-03502-7. PMID: 33128595
Transitional cell carcinoma of the renal pelvis or ureter: patterns of failure.
Cozad SC, Smalley SR, Austenfeld M, Noble M, Jennings S, Raymond R
Urology 1995 Dec;46(6):796-800. doi: 10.1016/S0090-4295(99)80346-X. PMID: 7502418

Diagnosis

Difference of oncological efficacy between two immune checkpoint inhibitors following first-line platinum-based chemotherapy in patients with unresectable, metastatic, advanced urothelial carcinoma: a multicenter real-world Japanese cohort.
Miyake M, Nishimura N, Oda Y, Miyamoto T, Iida K, Inoue K, Tachibana A, Yoshikawa T, Sakamoto K, Ohnishi M, Maesaka F, Takamatsu N, Mieda K, Ohmori C, Matsubara T, Tomizawa M, Shimizu T, Ohnishi K, Hori S, Morizawa Y, Gotoh D, Nakai Y, Torimoto K, Tanaka N, Fujimoto K; Nara Urological Research and Treatment Group
Int J Clin Oncol 2024 Sep;29(9):1311-1325. Epub 2024 Jun 18 doi: 10.1007/s10147-024-02573-5. PMID: 38888683
Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre real-world Japanese cohort.
Miyake M, Nishimura N, Oda Y, Miyamoto T, Ohmori C, Takamatsu N, Itami Y, Tachibana A, Matsumoto Y, Kiba K, Tomioka A, Yamamoto H, Okajima E, Masaomi K, Sakamoto K, Tomizawa M, Shimizu T, Ohnishi K, Hori S, Morizawa Y, Gotoh D, Nakai Y, Torimoto K, Tanaka N, Fujimoto K; Nara Urological Research and Treatment Group
Jpn J Clin Oncol 2024 Mar 9;54(3):329-338. doi: 10.1093/jjco/hyad170. PMID: 38061911
Switch-maintenance avelumab immunotherapy following first-line chemotherapy for patients with advanced, unresectable or metastatic urothelial carcinoma: the first Japanese real-world evidence from a multicenter study.
Miyake M, Shimizu T, Oda Y, Tachibana A, Ohmori C, Itami Y, Kiba K, Tomioka A, Yamamoto H, Ohnishi K, Nishimura N, Hori S, Morizawa Y, Gotoh D, Nakai Y, Torimoto K, Fujii T, Tanaka N, Fujimoto K
Jpn J Clin Oncol 2023 Mar 7;53(3):253-262. doi: 10.1093/jjco/hyac186. PMID: 36484294

Therapy

Difference of oncological efficacy between two immune checkpoint inhibitors following first-line platinum-based chemotherapy in patients with unresectable, metastatic, advanced urothelial carcinoma: a multicenter real-world Japanese cohort.
Miyake M, Nishimura N, Oda Y, Miyamoto T, Iida K, Inoue K, Tachibana A, Yoshikawa T, Sakamoto K, Ohnishi M, Maesaka F, Takamatsu N, Mieda K, Ohmori C, Matsubara T, Tomizawa M, Shimizu T, Ohnishi K, Hori S, Morizawa Y, Gotoh D, Nakai Y, Torimoto K, Tanaka N, Fujimoto K; Nara Urological Research and Treatment Group
Int J Clin Oncol 2024 Sep;29(9):1311-1325. Epub 2024 Jun 18 doi: 10.1007/s10147-024-02573-5. PMID: 38888683
Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre real-world Japanese cohort.
Miyake M, Nishimura N, Oda Y, Miyamoto T, Ohmori C, Takamatsu N, Itami Y, Tachibana A, Matsumoto Y, Kiba K, Tomioka A, Yamamoto H, Okajima E, Masaomi K, Sakamoto K, Tomizawa M, Shimizu T, Ohnishi K, Hori S, Morizawa Y, Gotoh D, Nakai Y, Torimoto K, Tanaka N, Fujimoto K; Nara Urological Research and Treatment Group
Jpn J Clin Oncol 2024 Mar 9;54(3):329-338. doi: 10.1093/jjco/hyad170. PMID: 38061911
Tailored immunotherapy approach with nivolumab with or without ipilimumab in patients with advanced transitional cell carcinoma after platinum-based chemotherapy (TITAN-TCC): a multicentre, single-arm, phase 2 trial.
Grimm MO, Grün CB, Niegisch G, Pichler M, Roghmann F, Schmitz-Dräger B, Baretton G, Schmitz M, Bolenz C, Foller S, Leucht K, Schumacher U, Schostak M, Meran J, Loidl W, Zengerling F
Lancet Oncol 2023 Apr;24(4):347-359. Epub 2023 Feb 28 doi: 10.1016/S1470-2045(23)00053-0. PMID: 36868252
Immune checkpoint inhibition in upper tract urothelial carcinoma.
Califano G, Ouzaid I, Verze P, Hermieu JF, Mirone V, Xylinas E
World J Urol 2021 May;39(5):1357-1367. Epub 2020 Oct 31 doi: 10.1007/s00345-020-03502-7. PMID: 33128595
Long-term results with M-VAC for advanced urothelial cancer: high relapse rate and low survival in patients with a complete response.
Igawa M, Urakami S, Shiina H, Ishibe T, Kadena H, Usui T
Br J Urol 1995 Sep;76(3):321-4. doi: 10.1111/j.1464-410x.1995.tb07708.x. PMID: 7551840

Prognosis

Long-term results with M-VAC for advanced urothelial cancer: high relapse rate and low survival in patients with a complete response.
Igawa M, Urakami S, Shiina H, Ishibe T, Kadena H, Usui T
Br J Urol 1995 Sep;76(3):321-4. doi: 10.1111/j.1464-410x.1995.tb07708.x. PMID: 7551840
Transitional cell carcinoma of the renal pelvis or ureter: patterns of failure.
Cozad SC, Smalley SR, Austenfeld M, Noble M, Jennings S, Raymond R
Urology 1995 Dec;46(6):796-800. doi: 10.1016/S0090-4295(99)80346-X. PMID: 7502418

Clinical prediction guides

Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre real-world Japanese cohort.
Miyake M, Nishimura N, Oda Y, Miyamoto T, Ohmori C, Takamatsu N, Itami Y, Tachibana A, Matsumoto Y, Kiba K, Tomioka A, Yamamoto H, Okajima E, Masaomi K, Sakamoto K, Tomizawa M, Shimizu T, Ohnishi K, Hori S, Morizawa Y, Gotoh D, Nakai Y, Torimoto K, Tanaka N, Fujimoto K; Nara Urological Research and Treatment Group
Jpn J Clin Oncol 2024 Mar 9;54(3):329-338. doi: 10.1093/jjco/hyad170. PMID: 38061911
Tailored immunotherapy approach with nivolumab with or without ipilimumab in patients with advanced transitional cell carcinoma after platinum-based chemotherapy (TITAN-TCC): a multicentre, single-arm, phase 2 trial.
Grimm MO, Grün CB, Niegisch G, Pichler M, Roghmann F, Schmitz-Dräger B, Baretton G, Schmitz M, Bolenz C, Foller S, Leucht K, Schumacher U, Schostak M, Meran J, Loidl W, Zengerling F
Lancet Oncol 2023 Apr;24(4):347-359. Epub 2023 Feb 28 doi: 10.1016/S1470-2045(23)00053-0. PMID: 36868252

Supplemental Content

Table of contents

    Practice guidelines

    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...